Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC
Category: #health  By Nikita Chaurasia  Date: 2020-03-30
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC

Esperion Therapeutics, a US-based public pharmaceutical company, reportedly unveiled that two pooled data analyses from its 4 Phase 3 clinical studies of NEXLETOL and outcomes from Phase 2 trial of NEXLIZET were showcased during the ACC.20/WCC.

In a poster session that was showcased by Harold E Bays, FOMA, MD, FTOS, FACE, FTOS, FNLA, FACC., it was highlighted that in Phase 2 trial, NEXLIZET lowered LDL-C significantly by a 40% mean as compared placebo, lowered hsCRP by 25% in comparison to the baseline, and further did not worsen glycemic control.

Along with the first poster, an additional poster session was conducted by Eric S. G. Stroes, MD., PhD. This poster signified that inside the pooled Phase 3 trials, NEXLETOL substantially decreased hsCRP in patients suffering from hypercholesterolemia irrespective of the intensity or presence of background statin treatment.

The third and final poster session was conducted by Maciej Banach, Ph.D., FESC, FAHA, MD. In the session it was highlighted that in Phase 3, NEXLETOL facilitated significant additional lowering of LDL-C while also significantly lowering other lipid endpoints, irrespective of background ezetimibe presence. Most notably, NEXLETOL’s safety profile was similar without or with background ezetimibe treatment.

Tim Mayleben, President and the Chief Executive Officer of Esperion stated that the company is thrilled with the final outcomes of Phase 2 trials that signifies NEXLIZET gained a 40 percent LDL-C lowering, a substantial 25 percent decrease in hsCRP and did not exacerbate glycemic control in patients suffering from Type 2 diabetes. The pooled analyses from Phase 3 LDL-C decreasing development program shows that NEXLETOL can be safely integrated with multiple LDL-C medicines, crucial to aid more patients to achieve their LDL-C objectives.

Mayleben further added that these analyses assure the safety and efficacy of the company’s medicines for millions of patients wanting to decrease their bad cholesterol levels.

 

Source credit: https://www.esperion.com/investors-media/press-releases/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Ford takes on GM, Tesla by debuting its first hands-free driving system

Ford takes on GM, Tesla by debuting its first hands-free driving system

By Nikita Chaurasia

Ford Motor Company, the American multinational automaker, is reportedly planning on introducing a hands-free driving feature on its 2021 Mustang Models as well as 2021 F-150 pickup truck through a software update, by the end of the year. The automob...

Oculus Quest 2 update to include wireless PC streaming, 120Hz mode

Oculus Quest 2 update to include wireless PC streaming, 120Hz mode

By Nikita Chaurasia

Oculus, a subsidiary of Facebook, Inc., that develops and manufactures virtual reality headsets, has recently announced that Oculus Quest 2’s new v28 software update will include native wireless desktop PC streaming as well as 120 Hz refresh ra...

Levi’s boosts its sales outlook for first half of 2021 on vaccine hopes

Levi’s boosts its sales outlook for first half of 2021 on vaccine hopes

By Nikita Chaurasia

Levi Strauss & Co., an American clothing company, has reportedly raised its half-yearly revenue growth projection, counting on COVID-19 vaccine rollouts to reinstate the popularity of its physical stores. The denim-maker had previously beaten est...